QPPV.COM KNOWLEDGE ASSESSMENT

Antibody–Drug Conjugates: Targeted Cytotoxic Delivery, Mechanisms of Toxicity and Pharmacovigilance

Test your understanding of the concepts covered by Antibody–Drug Conjugates: Targeted Cytotoxic Delivery, Mechanisms of Toxicity and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best captures the regulatory significance of an ADC medication-error report involving similarly named products?

It is relevant only if the patient experiences an adverse reaction It may represent both an individual safety case and evidence of a system-level risk requiring preventive action It should be excluded because medication errors are not pharmacovigilance information It demonstrates that the products have equivalent clinical effects

Question 2 of 10 A tumour loses antigen expression during treatment. Which conclusion about safety is most appropriate?

Loss of tumour antigen eliminates all subsequent ADC exposure Loss of antigen primarily affects productive tumour delivery and resistance, but systemic exposure to ADC or released payload may continue Loss of antigen guarantees increased bystander killing in all tissues Loss of antigen proves that any toxicity is unrelated to treatment

Question 3 of 10 Which aggregation strategy is most likely to support a balanced investigation of a potential ADC signal?

Aggregate only by preferred term across all medicines Aggregate only by antibody target and ignore the exact product Review the exact ADC and, where scientifically appropriate, compare by target, payload class, linker/release characteristics and phenotype Aggregate all cytotoxic medicines regardless of mechanism

Question 4 of 10 Which statement best describes the relevance of prior exposure to related agents in ADC safety assessment?

Prior therapy is relevant only if it used the identical ADC Prior therapy may alter organ reserve, baseline risk or cumulative injury and can complicate causal interpretation Prior exposure eliminates the possibility of a new ADC-related toxicity Prior therapy affects efficacy but never safety

Question 5 of 10 Which observation would most specifically support investigation of a construct-specific safety issue rather than a general target or payload effect?

The event occurs with multiple products sharing the same payload class The event occurs with multiple modalities acting on the same target The event appears concentrated with one ADC despite shared target and related payload class The event occurs in patients with advanced cancer

Question 6 of 10 Why should target expression in normal tissue be considered when assessing the safety of an ADC?

Normal-tissue expression proves that the antibody has no tumour selectivity Binding and processing in normal tissue can expose susceptible cells to the payload Normal tissues cannot internalise ADCs, so expression is relevant only to efficacy Target expression determines the drug-to-antibody ratio

Question 7 of 10 Why is exact product identification particularly important when several medicines contain the same antibody component?

The products are interchangeable if their antibody targets are identical Different conjugates can have different dosing, handling, payloads and safety profiles, and may be confused with unconjugated antibodies Exact identification matters only for commercial reporting The antibody name uniquely determines the linker and payload

Question 8 of 10 What is the main limitation of using a mechanistically plausible pathway as the basis for a causality conclusion?

Mechanistic pathways are never relevant to pharmacovigilance A plausible mechanism organises and strengthens a hypothesis but does not replace clinical, epidemiological and exposure evidence Mechanistic evidence is stronger than all observed clinical data Mechanistic reasoning can establish causality without a well-characterised phenotype

Question 9 of 10 A suspected toxicity occurs in a tissue with little apparent expression of the intended antigen. What is the most appropriate interpretation?

The event is unrelated to the ADC because target expression is absent The event proves that the target is expressed at high levels but has not been measured correctly Non-target uptake, extracellular processing, released payload exposure or alternative causes should be investigated The event must be attributed to the antibody Fc region

Question 10 of 10 What is the principal safety objective of linker stability during systemic circulation?

To ensure that all payload remains permanently attached to the antibody To prevent inappropriate systemic release while allowing productive release at the intended biological site To increase antibody affinity for the target antigen To eliminate the need for intracellular processing

QPPV.com

Antibody–Drug Conjugates: Targeted Cytotoxic Delivery, Mechanisms of Toxicity and Pharmacovigilance

Cookie Settings